Alpha$_1$-Proteinase Inhibitors

Policy Number: 2025D0067J
Effective Date: November 1, 2025

➲ Instructions for Use

Table of Contents **Page**

Related Commercial Policy
- Provider Administered Drugs – Site of Care

Community Plan Policy
- Alpha$_1$-Proteinase Inhibitors

Coverage Rationale

➲ See Benefit Considerations

Alpha$_1$-proteinase inhibitors (Aralast NP™, Glassia™, Prolastin®-C, and Zemaira®) are proven for chronic augmentation and maintenance therapy of patients with emphysema due to congenital deficiency of alpha$_1$-proteinase inhibitor (A$_1$-PI), also known as alpha$_1$-antitrypsin (AAT) deficiency.

Alpha$_1$-proteinase inhibitors (Aralast NP™, Glassia™, Prolastin®-C, and Zemaira®) are medically necessary for the treatment of emphysema due to congenital deficiency of alpha$_1$-proteinase inhibitor (A$_1$-PI) in patients who meet all of the following criteria:

- For **initial therapy**, **all** of the following:
  - Diagnosis of congenital alpha1-antitrypsin deficiency confirmed by **one** of the following:
    - Pi*ZZ, Pi*Z(null) or Pi*(null)(null) protein phenotypes (homozygous); **or**
    - Other rare AAT disease-causing alleles associated with serum alpha$_1$-antitrypsin (AAT) level < 11 µmol/L [e.g., Pi (Malton, Malton)]

    and
  - Circulating serum concentration of alpha$_1$-antitrypsin (AAT) level < 11 µmol/L (which corresponds to < 80 mg/dl if measured by radial immunodiffusion or < 57 mg/dl if measured by nephelometry); **and**
  - Continued optimal conventional treatment for emphysema (e.g., bronchodilators, supplemental oxygen if necessary); **and**
  - Current nonsmoker; **and**
  - Diagnosis of emphysema confirmed with pulmonary function testing; **and**
  - Dosing is in accordance with the United States Food and Drug Administration approved labeling; **and**
  - Initial authorization will be for no more than 12 months
- For **continuation therapy**, **all** of the following:
  - Patient is currently receiving therapy for emphysema due to congenital alpha$_1$-antitrypsin (AAT) deficiency; **and**
  - Documentation of a positive clinical response (e.g., decreased frequency of exacerbations, improvement in symptom burden, slowed rate of FEV$_1$); **and**
  - Patient remains a nonsmoker; **and**
  - Dosing is in accordance with the United States Food and Drug Administration approved labeling; **and**
  - Reauthorization will be for no more than 12 months

Alpha$_1$-proteinase inhibitor is unproven for:

- Conditions other than emphysema associated with alpha$_1$-antitrypsin deficiency

- Cystic fibrosis

Applicable Codes

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Listing of a code in this policy does not imply that the service described by the code is a covered or non-covered health service. Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Guidelines may apply.

HCPCS Code	Description
J0256	Injection, alpha 1-proteinase inhibitor, human, 10 mg, not otherwise specified
J0257	Injection, alpha 1-proteinase inhibitor (human), (Glassia), 10 mg

Diagnosis Code	Description
E88.01	Alpha-1-antitrypsin deficiency

Background

Deficiency of alpha$_1$-proteinase inhibitor (A_1-PI), also known as alpha$_1$-antitrypsin (AAT) deficiency, is characterized by reduced levels of A_1-PI in the blood and lungs. A_1-PI deficiency is an autosomal, co-dominant, hereditary disorder. Patients with severe A_1-PI deficiency have increased levels of neutrophil and neutrophil elastase levels in lung epithelial lining fluid which results in unopposed destruction of the connective tissue framework of the lung parenchyma. A_1-PI (human) therapy augments the level of the deficient protein and theoretically corrects the imbalance between neutrophil elastase and protease inhibitors, which may protect the lower respiratory tract.

Benefit Considerations

Some Certificates of Coverage allow for coverage of experimental/investigational/unproven treatments for life-threatening illnesses when certain conditions are met. The member specific benefit plan document must be consulted to make coverage decisions for this service. Some states mandate benefit coverage for off-label use of medications for some diagnoses or under some circumstances when certain conditions are met. Where such mandates apply, they supersede language in the benefit document or in the medical or drug policy.

Clinical Evidence

Proven

Alpha$_1$-Proteinase Inhibitor (A_1-PI) Deficiency [i.e., Alpha$_1$-Antitrypsin (AAT) Deficiency]

Tonellis et al. examined the effect of alpha-1 antitrypsin augmentation therapy on FEV_1 decline in patients with alpha-1 antitrypsin deficiency (AATD) related lung disease enrolled in the Alpha-1 Foundation DNA and Tissue Bank study. Patients were included if they had a proven PI ZZ genotype and at least two recorded post-bronchodilator FEV_1 measurements, 6 months apart or more. The 164 patients were then divided into 2 groups: 1) “augmented” (patients who were receiving augmentation therapy at time of the inclusion in the study), 2) “nonaugmented“(patients who were not receiving augmentation therapy at the time of the inclusion in the study). Mean age of the included patients was 60 years, 52% were females, 94% were white and 78% ex-smokers. Researchers reported a mean FEV_1 at baseline was 1.7 L and the mean FEV_1 % of predicted was 51.3%. The mean follow-up time was 41.7 months. Of the 164 patients, 124 (76%) patients received augmentation therapy (augmented group) while 40 patients (24%) did not (non-augmented group). When adjusted by age at baseline, sex, smoking status, baseline FEV_1 % of predicted, the mean overall change in FEV_1 reported was 47.6 mL/year, favoring the augmented group (decline in FEV_1 10.6 +/- 21.4 mL/year) in comparison with the non-augmented group (decline in FEV_1 -36.96 +/- 12.1 mL/year) ($p = 0.05$). Beneficial change in FEV_1 were observed in ex-smokers and the group with initial FEV_1 % of predicted of < 50%. There were no differences were observed in mortality. Researchers concluded that augmentation therapy improves lung function in subjects with AATD when adjusted by age, gender, smoking status, and baseline FEV % of predicted. Additionally, the beneficial effects were observed in ex-smoker subjects with FEV_1 below 50% of predicted.

A multicenter, retrospective cohort study evaluated the progression of emphysema in patients with alpha$_1$-protease inhibitor (alpha$_1$-Pi) deficiency before and during a period in which they received treatment with alpha$_1$-Pi augmentation therapy. Ninety-six patients with severe alpha$_1$-Pi deficiency receiving weekly treatment with human alpha$_1$-Pi (60 mg/kg of body weight). A minimum of two lung function measurements before and two lung function measurements after augmentation therapy was started was performed. Lung function data were followed up for a minimum of 12 months both before and during treatment (mean, 47.5 months, and 50.2 months, respectively). Patients were grouped according to the severity of their lung function impairment. A majority of patients had PiZ phenotypes and frequency did not differ between male and female patients. Change in FEV_1 was compared during non-treatment and treatment periods. The reported decline in FEV_1 was significantly lower during the treatment period (49.2 mL/yr vs. 34.2 mL/yr, p = 0.019) in all 96 patients. In patients with $FEV_1 > 65\%$, IV alpha$_1$-Pi treatment reduced the decline in FEV_1 by 73.6 mL/yr (p = 0.045). Seven individuals had a rapid decline of FEV_1 before treatment, and the loss in FEV_1could be reduced from 256 mL/yr to 53 mL/yr (p = 0.001). This study showed a significant reduction in the loss of lung function during the period in which patients with α1 -Pi deficiency received augmentation therapy, which reflected a slower progress of their lung emphysema. Patients with well-maintained lung function and a rapid decline profited most from augmentation therapy. Researchers concluded that early diagnosis and early start of augmentation therapy may prevent accelerated loss of lung tissue.

As part of a National Heart, Lung, and Blood Institute Registry of Patients with Severe Deficiency of Alpha-1-Antitrypsin, patients ≥ 18 years of age with a serum alpha$_1$-antitrypsin (alpha$_1$-AT) levels ≤ 11 microM or PiZZ genotype were followed for 3.5 to 7 years with spirometry measurements every 6 to 12 months. Of the 1,129 patients enrolled in the observational study, 382 (34%) never received augmentation therapy, 390 (35%) always received therapy, and 357 (32%) were partly receiving therapy while in the Registry. Results showed that those patients that had received alpha$_1$-antitrypsin augmentation therapy had decreased mortality [risk ratio (RR) = 0.64, 95% CI: 0. 43 to 0.94, p = 0.02] as compared with those not receiving therapy. Furthermore, use of augmentation therapy was associated with lower mortality in the subgroup with initial FEV_1 values of 35 to 49% predicted (ATS Stage II) (RR 5 0.21, 95% CI 5 0.09 to 0.50, p < 0.001). FEV_1 decline was not different between augmentation-therapy groups (p = 0.40). Researchers concluded that patients that received augmentation therapy have a better survival than do patients not on therapy, although these differences may have been due to other factors.

Seershholm et al. conducted a non-randomized study which evaluated the effect of α_1-antitrypsin augmentation (α1-AT) therapy on patients with α_1-antitrypsin deficiency (α_1-ATD) by comparing the annual decline in FEV_1 in a treated group of ex-smokers in Germany and an untreated group of ex-smokers in Denmark. From the files of the Danish α_1-ATD register, 97 ex-smokers were included with the following criteria: PiZZ phenotype or having a α1-AT serum level of less than 12 µmol/L.; age > 25 years at entry; and have results of two or more spirometries at least 1 year apart available. German patients (n = 198) utilized in the analysis met the following inclusion criteria: have the PiZZ phenotype; be ex-smokers before entering the surveillance study; have received weekly infusions of α1-AT 60 mg/kg augmentation therapy for at least 1 year; and have had two or more spirometries at least 1 year apart performed during the treatment period. The decline in FEV_1 was compared between the two treatment groups by random effects modeling which included age at entry and follow- up time as covariates, treatment (Denmark versus Germany), gender, and initial FEV_1 as fixed parameters, and the individual patients as random effects parameters. The reported decline in FEV_1 in the treated group was significantly lower than in the untreated group, with annual declines of 53 mL/year (95%CI 48-58 mL/year) and 75 mL/year (95% CI 63-87 mL/year), respectively (p = 0.02). Both groups differed with respect to gender and initial FEV_1% predicted, however, gender did not have any influence on FEV_1 decline. Stratification by initial FEV_1% predicted showed a significant effect of the treatment only in the group of patients with an initial FEV_1% predicted of 31-65%, and FEV1 decline was reduced by 21 mL/year. Researchers concluded that this nonrandomized study suggested that weekly infusion of human α_1-antitrypsin in patients with moderately reduced lung function may slow the annual decline in FEV_1.

The treatment of 21 patients with alpha-1 antitrypsin deficiency with plasma-derived alpha-1 proteinase inhibitor for 6 months demonstrated the safety and effectiveness of the drug in producing elevations in serum and lung fluid levels of AAT. Patients administered intravenous doses of 60 milligrams/kilogram/week alpha-1 proteinase inhibitor (alpha-1 PI) at a rate of 2 mg/kg/min. Samples of serum and alveolar fluid were obtained prior to treatment and at various intervals after the infusions. Following administration of alpha-1 PI, trough serum AAT levels were 126 mg/dL compared to 30 mg/dL at baseline. The AAT level in the fluid from the epithelial lining of the lungs was measured at 1.89 micromoles (mcmol) 6 days after the infusion compared to a baseline level of 0.46 mcmol. Alpha-1 PI infusions resulted in an improved capacity to inhibit neutrophil elastase in the lower respiratory tract for the patients as demonstrated by an increase in the average anti-neutrophil elastase capacity in the lung fluid to 1.65 mcmol, compared to a baseline of 0.81 mcmol prior to therapy. Additionally, patients also demonstrated an increase in serum anti-neutrophil elastase capacity to 13.3 mcmol, as compared to 5.4 mcmol at baseline. No changes in pulmonary function tests were detected after 6 months of treatment. Adverse reactions were limited to 4 episodes of self-limited fever, 3 of which were related to contamination of the product with endotoxin. No evidence for formation of antibodies or immune complexes to treatment could be demonstrated.

Researchers concluded that the study effectively demonstrated the reversibility of the alpha-1 antitrypsin deficiency in the blood and lung fluid of the patients treated with alpha-1 PI therapy.

Unproven

Cystic Fibrosis

A randomized controlled trial of alpha-1 proteinase inhibitor administration for 4 weeks to patients with cystic fibrosis (CF) showed reduction in a variety of pulmonary inflammatory mediators, including neutrophil elastase, although lung function itself was unchanged. Clinical studies of treatment with aerosolized alpha-1 proteinase inhibitor in cystic fibrosis have shown some promise; however larger studies with relevant clinical endpoints are needed to validate efficacy.

Miscellaneous

For conditions associated with alpha-1 proteinase inhibitor deficiency other than chronic obstructive lung disease, a review found only case reports of patients treated with alpha-1 proteinase inhibitor on a compassionate basis for refractory bronchial asthma, fibromyalgia, panniculitis, and vasculitis. Although all patients experienced a positive response to treatment, the authors concluded that further laboratory studies in animal and humans as well as larger clinical trials are warranted in order to determine efficacy of augmentation therapy in these conditions.

U.S. Food and Drug Administration (FDA)

This section is to be used for informational purposes only. FDA approval alone is not a basis for coverage.

Aralast NP, Prolastin-C, Glassia, and Zemaira are all $alpha_1$-proteinase inhibitors (human) FDA-labeled for chronic augmentation therapy in patients having congenital deficiency of $alpha_1$-proteinase inhibitor (A_1-PI), also known as $alpha_1$-antitrypsin (AAT) deficiency, with clinically evident emphysema.

- Effects on pulmonary exacerbations and on the progression of emphysema in AAT deficiency has not been demonstrated in randomized, controlled clinical trials
- Clinical data demonstrating the long-term effects of chronic augmentation or replacement therapy of individuals treated with alpha1-proteinase inhibitors are not available
- Alpha1-proteinase inhibitors are not indicated for treatment of lung disease in patients whom congenital A1-PI deficiency has not been established
- Alpha1-proteinase inhibitors are derived from pooled human plasma and may carry a risk of transmitting infectious agents, e.g., viruses and theoretically, the Creutzfeldt-Jakob disease (CJD) agent
- Aralast NP, Glassia, Prolastin-C and Zemaira are contraindicated in IgA deficient patients with antibodies against IgA

References

1. Aralast NP [package insert]. Westlake Village, CA: Baxalta US Inc.; May 2025.
2. Glassia [package insert]. Lexington, MA: Takeda Pharmaceuticals U.S.A., Inc.; February 2025.
3. Prolastin-C [package insert]. Research Triangle Park, NC: Grifols Therapeutics, Inc.; January 2022.
4. Zemaira [package insert]. Kankakee, IL: CSL Behring LLC; January 2024.
5. Alpha-1-proteinase inhibitor human. Micromedex® Healthcare Series. Thomson Reuters (Healthcare) Inc. [database online]. Available at: www.micromedexsolutions.com. Accessed September 9, 2025.
6. Gold Standard, Inc. Alpha-1-proteinase inhibitor. Clinical Pharmacology [database online]. Available at: https://clinicalkey.com/pharmacology. Accessed September 9, 2025.
7. American Thoracic Society / European Respiratory Society Statement: Standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med. 2003; 168:818-900.
8. Marciniuk DD, Hernandez P, Balter M, et al. Alpha-1 antitrypsin deficiency targeted testing and augmentation therapy: A Canadian Thoracic Society clinical practice guideline. Canadian Respiratory Journal 2012;19(2):109-116.
9. Griese M, et al. alpha1-Antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients. European Respiratory Journal 2007;29(2):240-50.
10. Griese M, Kappler M, Gaggar A, Hartl D. Inhibition of airway proteases in cystic fibrosis lung disease. European Respiratory Journal 2008;32(3):783-95.
11. Blanco I, Lara B, de Serres F. Efficacy of alpha1-antitrypsin augmentation therapy in conditions other than pulmonary emphysema. Orphanet Journal of Rare Diseases 2011; 6:14.

12. Tonelli AR, Rouhani F, Li N, et al. Alpha-1-antitrypsin augmentation therapy in deficient individuals enrolled in the Alpha-1 Foundation DNA and Tissue Bank. Int J Chron Obstruct Pulmon Dis. 2009; 4:443-52.
13. Marciniuk DD, Hernandez P, Balter M, et al. Alpha-1 antitrypsin deficiency targeted testing and augmentation therapy: a Canadian Thoracic Society clinical practice guideline. Can Respir J. 2012 Mar-Apr;19(2):109-16.
14. Stoller JK. Clinical manifestations, diagnosis, and natural history of alpha-1 antitrypsin deficiency. UpToDate. Last updated: October 1, 2024. Accessed September 9, 2025.
15. Sandhaus RA, Turino G, Brantly ML, et al. The Diagnosis and Management of Alpha-1 Antitrypsin Deficiency in the Adult. *Chronic Obstr Pulm Dis.* 2016;3(3):668-682.
16. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2025 report). Available at http://www.ginasthma.org. Accessed September 9, 2025.

Policy History/Revision Information

Date	Summary of Changes
11/01/2025	**Supporting Information** • Updated *References* section to reflect the most current information • Archived previous policy version 2024D0067I

Instructions for Use

This Medical Benefit Drug Policy provides assistance in interpreting UnitedHealthcare standard benefit plans. When deciding coverage, the member specific benefit plan document must be referenced as the terms of the member specific benefit plan may differ from the standard plan. In the event of a conflict, the member specific benefit plan document governs. Before using this policy, please check the member specific benefit plan document and any applicable federal or state mandates. UnitedHealthcare reserves the right to modify its Policies and Guidelines as necessary. This Medical Benefit Drug Policy is provided for informational purposes. It does not constitute medical advice.

This Medical Benefit Drug Policy may also be applied to Medicare Advantage plans in certain instances. In the absence of a Medicare National Coverage Determination (NCD), Local Coverage Determination (LCD), or other Medicare coverage guidance, CMS allows a Medicare Advantage Organization (MAO) to create its own coverage determinations, using objective evidence-based rationale relying on authoritative evidence (Medicare IOM Pub. No. 100-16, Ch. 4, §90.5).

UnitedHealthcare may also use tools developed by third parties, such as the InterQual® criteria, to assist us in administering health benefits. UnitedHealthcare Medical Benefit Drug Policies are intended to be used in connection with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.